These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21681601)

  • 1. Tumour topoisomerase II alpha protein expression and outcome after adjuvant dose-dense anthracycline-based chemotherapy.
    Nikolényi A; Uhercsák G; Csenki M; Hamar S; Csörgo E; Tánczos E; Thurzó L; Brodowicz T; Wagnerova M; Kahán Z
    Pathol Oncol Res; 2012 Jan; 18(1):61-8. PubMed ID: 21681601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
    Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.
    Fountzilas G; Valavanis C; Kotoula V; Eleftheraki AG; Kalogeras KT; Tzaida O; Batistatou A; Kronenwett R; Wirtz RM; Bobos M; Timotheadou E; Soupos N; Pentheroudakis G; Gogas H; Vlachodimitropoulos D; Polychronidou G; Aravantinos G; Koutras A; Christodoulou C; Pectasides D; Arapantoni P
    J Transl Med; 2012 Jan; 10():10. PubMed ID: 22240029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
    Fountzilas G; Dafni U; Bobos M; Kotoula V; Batistatou A; Xanthakis I; Papadimitriou C; Kostopoulos I; Koletsa T; Tsolaki E; Televantou D; Timotheadou E; Koutras A; Klouvas G; Samantas E; Pisanidis N; Karanikiotis C; Sfakianaki I; Pavlidis N; Gogas H; Linardou H; Kalogeras KT; Pectasides D; Dimopoulos MA
    BMC Cancer; 2013 Mar; 13():163. PubMed ID: 23537287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topoisomerase II alpha and microtubule-associated protein-tau as a predictive marker in axillary lymph node positive breast cancer.
    Won HS; Lee KE; Sung SH; Choi MY; Jo JY; Nam EM; Mun YC; Seong CM; Lee SN
    Tumori; 2014; 100(1):80-6. PubMed ID: 24675496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
    O'Malley FP; Chia S; Tu D; Shepherd LE; Levine MN; Bramwell VH; Andrulis IL; Pritchard KI
    J Natl Cancer Inst; 2009 May; 101(9):644-50. PubMed ID: 19401546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
    Di Leo A; Desmedt C; Bartlett JM; Piette F; Ejlertsen B; Pritchard KI; Larsimont D; Poole C; Isola J; Earl H; Mouridsen H; O'Malley FP; Cardoso F; Tanner M; Munro A; Twelves CJ; Sotiriou C; Shepherd L; Cameron D; Piccart MJ; Buyse M;
    Lancet Oncol; 2011 Nov; 12(12):1134-42. PubMed ID: 21917518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
    Press MF; Sauter G; Buyse M; Bernstein L; Guzman R; Santiago A; Villalobos IE; Eiermann W; Pienkowski T; Martin M; Robert N; Crown J; Bee V; Taupin H; Flom KJ; Tabah-Fisch I; Pauletti G; Lindsay MA; Riva A; Slamon DJ
    J Clin Oncol; 2011 Mar; 29(7):859-67. PubMed ID: 21189395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer.
    Schindlbeck C; Mayr D; Olivier C; Rack B; Engelstaedter V; Jueckstock J; Jenderek C; Andergassen U; Jeschke U; Friese K
    J Cancer Res Clin Oncol; 2010 Jul; 136(7):1029-37. PubMed ID: 20052594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.
    Arriola E; Rodriguez-Pinilla SM; Lambros MB; Jones RL; James M; Savage K; Smith IE; Dowsett M; Reis-Filho JS
    Breast Cancer Res Treat; 2007 Dec; 106(2):181-9. PubMed ID: 17260090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer.
    Şahin S; Işık Gönül İ; Çakır A; Seçkin S; Uluoğlu Ö
    Int J Surg Pathol; 2016 Oct; 24(7):607-13. PubMed ID: 27284123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
    Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.
    Fountzilas G; Christodoulou C; Bobos M; Kotoula V; Eleftheraki AG; Xanthakis I; Batistatou A; Pentheroudakis G; Xiros N; Papaspirou I; Koumarianou A; Papakostas P; Bafaloukos D; Skarlos DV; Kalogeras KT
    J Transl Med; 2012 Oct; 10():212. PubMed ID: 23092535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients.
    Hertel PB; Tu D; Ejlertsen B; Jensen MB; Balslev E; Jiang S; O'Malley FP; Pritchard KI; Shepherd LE; Bartels A; Brünner N; Nielsen TO
    Breast Cancer Res Treat; 2012 Feb; 132(1):225-34. PubMed ID: 22160637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer.
    Sparano JA; Goldstein LJ; Davidson NE; Sledge GW; Gray R
    Breast Cancer Res Treat; 2012 Jul; 134(2):751-7. PubMed ID: 22706628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).
    Bartlett JM; Munro AF; Dunn JA; McConkey C; Jordan S; Twelves CJ; Cameron DA; Thomas J; Campbell FM; Rea DW; Provenzano E; Caldas C; Pharoah P; Hiller L; Earl H; Poole CJ
    Lancet Oncol; 2010 Mar; 11(3):266-74. PubMed ID: 20079691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microvessel density and status of p53 protein as potential prognostic factors for adjuvant anthracycline chemotherapy in retrospective analysis of early breast cancer patients group.
    Biesaga B; Niemiec J; Ziobro M
    Pathol Oncol Res; 2012 Oct; 18(4):949-60. PubMed ID: 22549273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer.
    Zhong W; Yang Y; Zhang A; Lin W; Liang G; Ling Y; Zhong J; Yong J; Liu Z; Tian Z; Lin Q; Luo Q; Li Y; Gong C
    Breast Cancer; 2020 Nov; 27(6):1147-1157. PubMed ID: 32780321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic potential of topoisomerase IIα and HER2 in a retrospective analysis of early advanced breast cancer patients treated with adjuvant anthracycline chemotherapy.
    Biesaga B; Niemiec J; Ziobro M; Wysocka J; Kruczak A
    Breast; 2011 Aug; 20(4):338-50. PubMed ID: 21507646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.